QUOTE AND NEWS
FiercePharma  8 hrs ago  Comment 
The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock...
Market Intelligence Center  May 22  Comment 
Perrigo (PRGO) is a good candidate for a covered call at the $195.00 level. The Jul. '15 call at that price should fetch a credit of about $12.00, which means the entire position has a net debit of about $186.26. This trade has 4.54% downside...
Market Intelligence Center  May 21  Comment 
The patented options-trade picking algorithms used by MarketIntelligenceCenter.com found a trading opportunity with Perrigo (PRGO) that should provide a 5.44% return in just 57 days. Sell one Jul. '15 call at the $195.00 level for each 100 shares...
newratings.com  May 19  Comment 
Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, ...
FiercePharma  May 18  Comment 
Perrigo's not opposed to striking a pact with Mylan--as long as the price is right. The bad news for its suitor, though, is that right now, it's nowhere close.
newratings.com  May 12  Comment 
Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, ...
newratings.com  May 12  Comment 
CANONSBURG (dpa-AFX) - Dutch generic drug maker Mylan N.V.'s (MYL) Executive Chairman Robert Coury may sweeten the company's cash-and-stock offer for Perrigo Co. (PRGO) by adding terms to reduce the risk to its shareholders,...
FiercePharma  May 11  Comment 
So far, Perrigo hasn't seemed too keen on selling itself to generics giant Mylan. It's rejected the U.S. drugmaker three times. But word has it that Perrigo tried to link arms with another generics giant on the block--and that's Mylan suitor Teva.
Motley Fool  May 7  Comment 
Who will buy who? Mylan extends an offer for a rival, while a separate competitor makes a play for Mylan.
Clusterstock  May 7  Comment 
Hedge-fund manager J. Kyle Bass has snapped up a large long position in Perrigo, an Irish manufacturer of over-the-counter pharmaceuticals, Business Insider has learned. Perrigo (PRGO) is now Hayman Capital's second-largest equity...




 

Perrigo Company is a global health-care supplier and the world's largest manufacturer of over-the-counter pharmaceuticals for the store brand market. The company develops, distributes, and manufactures over-the-counter and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients, and consumer products.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki